Short Communication
Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer
Shreya Gupta, James D. McDonald, Reed I. Ayabe, Tahsin M. Khan, Lauren A. Gamble, Surajit Sinha, Cathleen Hannah, Andrew M. Blakely, Jeremy L. Davis, Jonathan M. Hernandez
